AI Cuts Melanoma Recurrence by 49% in Moderna Trial
alex_verem · x · 2026-08-25
A 1,137-patient trial by Moderna and Merck shows that personalized mRNA cancer therapy combined with Keytruda reduced the risk of recurrence or death by 49%. The treatment uses a machine learning pipeline to select the top 34 immune-triggering mutations from thousands of candidates to create a custom mRNA shot. The post highlights the immense value of such "background" AI models in healthcare compared to consumer applications like email writing.
Related event: Moderna's AI-Assisted mRNA Cancer Vaccine Cuts Recurrence Risk by 49%(2 posts)→
More from Apps
- AI startup idea: Auto-generate apology videos for busy tech YouTubers — Aizkmusic · 2026-08-25
- Claude down, back up, now burning tokens with no dev response — RileyRalmuto · 2026-08-25
- 90s Minimax video rendered in 1h on RTX 5060Ti — DaExChef · 2026-08-25
- You can change the reasoning on GPT live, a hidden feature discovered — ChrisGPT · 2026-08-25
- AI-powered agriculture rises in Africa via satellites and chatbots — pastramimachine · 2026-08-25
- How a cleaning supply company uses AI to expand territories — _sonith · 2026-08-25